ImmunityBio Inc. (26CA)
XDUS
Delayed Data
Oct 14, 2026, 06:00 AM
Day's Range
8.7052 wk Range
1.70Overview - 26CA - ImmunityBio Inc.
Key Statistics
Valuation
Enterprise Value
429.74M
P/E (Trailing)
‪-21.99‬
PEG Ratio
‪-0.18‬
Price / Book
‪-8.39‬
EV / EBITDA
‪-1.51‬
Profitability
Gross Margin
‪99.41%‬
Profit Margin
‪99.33%‬
Operating Margin
‪-211.03%‬
Return on Assets
‪-70.01%‬
Return on Equity
‪70.33%‬
Ownership
Shares Outstanding
1.05B
Price stats
50-Day Avg
‪6.78‬
200-Day Avg
‪6.23‬
Peers - 26CA - ImmunityBio Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 26CAXDUSImmunityBio Inc.+74.71%52-week change-22.00P/E (Trailing)‪99.33%‬Profit Margin
- 0QFXDUSModerna Inc.+88.57%52-week change—P/E (Trailing)—Profit Margin
- 2LBXDUSIovance Biotherapeutics Inc.+83.47%52-week change-10.55P/E (Trailing)‪34.27%‬Profit Margin
- 0MEXDUSTwist Bioscience Corporation+80.08%52-week change-108.42P/E (Trailing)‪50.72%‬Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+76.32%52-week change-38.38P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines, Inc.+75.52%52-week change-28.70P/E (Trailing)—Profit Margin
- 7BGXDUSOncoinvent ASA+72.12%52-week change-0.05P/E (Trailing)—Profit Margin
Profile Summary - 26CA - ImmunityBio Inc.
About
ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
